Famn Pharma Private Limited - Due diligence report

A 360° intelligence report on Famn Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and dis…

2019-07-30 New Delhi, Delhi Active Unlisted
Share
View plans Plan
FP Famn Pharma Private Limited
View plans Plan
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Famn Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
90/100
Trust Score
Low Risk

Famn Pharma Private Limited is assessed as Low Risk with a Trust Score of 90/100. Famn Pharma Private Limited is an active private limited indian non-government company incorporated in 2019, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 15 Jul 2026 from the latest processed filings. Famn Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
90/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 3 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.

Charges position: 1 open (1.35 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Axis Bank Limited1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
Neelam girishkumar Singh 01234567 Director 01/04/2018 6 yrs Approved
SUNJEET KUMAR SINGH 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2020 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +38% over 2 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 6 years.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence94/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment68/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 1.35 cr already registered.
  • Compliance record supports lending.
Investor view90/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 8 events
30 Sep 2025
Last AGM held
Annual general meeting
10 Jun 2025
Charge created
Axis Bank Limited - 1.35 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
22 Jun 2024
Director ceased
DEVENDRA GIRISHBHAI SINGH
11 Feb 2023
Director appointed
SUNJEET KUMAR SINGH (Director)
06 Feb 2021
Director ceased
RENU RAGHAV
30 Jul 2019
Incorporated
Registered with Roc Delhi
Director appointed
Neelam girishkumar Singh (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 2 financial year(s).
Net profit margin moved from 61% to 38%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2020 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Medicure Lifesciences India Private Limited U01119TG2008PTC056971 Ranga Reddy, Telangana, India
Leharsh Exports And Services Private Limited U51420OR2005PTC008360 Rourkela, Orissa, India
Dmv Impex Private Limited U74120UP2013PTC058645 Lucknow, Uttar Pradesh, India
Quin Chem Private Ltd U24117TN1992PTC023816 Chennai-23, Tamil Nadu, India
Firstview Trading Private Limited U51909WB2018PTC228935 Kolkata, West Bengal, India
Rerout Private Limited U74999MH2014PTC259340 Mumbai, Maharashtra, India
Verdant Scientech India Private Limited U32204TG2013PTC086179 Hyderabad, Telangana, India
Pisto Oil And Fats Private Limited U15140MH1994PTC081047 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Famn Pharma Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Famn Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Famn Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 90/100, distress signals and MSME payment-delay disclosures - know whether Famn Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Famn Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Famn Pharma Private Limited an active company?

Famn Pharma Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Famn Pharma Private Limited financially healthy?

Famn Pharma Private Limited has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.

Should I do business with Famn Pharma Private Limited?

Its overall Trust Score is 90/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Famn Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Famn Pharma Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Famn Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Famn Pharma Private Limited?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.